A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects, Subjects With Type 1 Diabetes Mellitus, and Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Insulin lispro (Primary) ; MK-1092 (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 02 Apr 2018 Type 2 diabetes patients were included in the study.Also planned patient number got changed from 76 to 85 and treatment arm for type 2 diabetes mellitus patients added.
- 02 Apr 2018 Planned number of patients changed from 76 to 85.
- 11 Oct 2017 Planned End Date changed from 22 Jun 2018 to 21 Sep 2018.